The attenuating and potentiating effects of traditional Chinese medicine in immune checkpoint therapy
10.12092/j.issn.1009-2501.2024.03.013
- Author:
Zhipeng ZHANG
1
;
Jianhui TIAN
1
;
Ziqi CHEN
2
;
Jianhui TIAN
3
Author Information
1. Oncology Research Center, Hospital of Traditional Chinese Medicine, Affiliated to Shanghai University of Traditional Chinese Medicine
2. Laboratory Center, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine
3. Oncology Clinical Research Center, Hospital of Traditional Chinese Medicine, Affiliated to Shanghai University of Traditional Chinese Medicine
- Publication Type:Journal Article
- Keywords:
adverse reaction;
immune checkpoint;
immunotherapy;
malignant tumours;
traditional Chinese medicine
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2024;29(3):339-347
- CountryChina
- Language:Chinese
-
Abstract:
Immunotherapy has become a global focus in cancer clinical practice and scientific research. In the past two years, PD-1\PD-L1 and CTLA-4 inhibitors, especially Nivolumab, Pembrolizumab, Atezolizumab and Lpilimumab, have been used in non-small cell lung cancer, colon cancer. Promising results have been obtained in malignancies such as melanoma and urinary tract cancer. Traditional Chinese medicine has a long history in China. Modulating immune checkpoints has certain advantages in treating malignant tumors, and it has shown good efficacy in improving its adverse events. This article reviews the role of traditional Chinese medicine in regulating immune checkpoints and improving adverse reactions and its application prospects in immunomodulatory treatment.
